Preclinical Murine Models for Lung Cancer: Clinical Trial Applications

EML4-ALK Fusion Lung Cancer: A Rare Acquired Event

(2015) Sven Perner et al.   NEOPLASIA

LKB1/AMPK/mTOR Signaling Pathway in Non-small-cell Lung Cancer

(2013) Dong Han et al.   Asian Pacific Journal of Cancer Prevention

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone:in vivostudies using a CYP2A13-humanized mouse model

(2013) Vandana Megaraj et al.   CARCINOGENESIS

Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer

(2013) Shirish M. Gadgeel et al.   Clinical Lung Cancer

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells

(2013) Yuji Sakuma et al.   LABORATORY INVESTIGATION

Life in the Fast Lane: Mammalian Disease Models in the Genomics Era

(2012) Lukas E. Dow et al.   CELL

Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor Models

(2011) Ayumu Taguchi et al.   CANCER CELL

A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference

(2011) Prem K. Premsrirut et al.   CELL

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

(2010) David E. Gerber et al.   CANCER CELL

Patient-Derived First Generation Xenografts of Non-Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy

(2010) X. Dong et al.   CLINICAL CANCER RESEARCH

The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer

(2010) T. John et al.   CLINICAL CANCER RESEARCH

Progress and applications of mouse models for human lung cancer

(2010) S. de Seranno et al.   EUROPEAN RESPIRATORY JOURNAL

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer

(2010) T. G. Oliver et al.   GENES & DEVELOPMENT

Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer

(2010) Mark A. Socinski et al.   Journal of Thoracic Oncology

Crizotinib — Latest Champion in the Cancer Wars?

(2010) Bengt Hallberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane

(2009) Zhongling Feng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts

(2009) A. A. Memon et al.   CANCER RESEARCH

Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo

(2009) E. Ichihara et al.   CANCER RESEARCH

Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-Small Cell Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding Protein-3, Tumor Cell Proliferation, and Angiogenic Factors

(2009) S. Akhtar et al.   CLINICAL CANCER RESEARCH

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

(2009) K. Politi et al.   Disease Models & Mechanisms

Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?☆

(2009) Johannes Merk et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

(2009) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer

(2009) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2009) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas

(2009) Yinghui Zhou et al.   NATURE BIOTECHNOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH

Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers

(2008) I. Fichtner et al.   CLINICAL CANCER RESEARCH

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

(2008) Jenifer L. Marks et al.   Journal of Thoracic Oncology

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer

(2008) K A Kwei et al.   ONCOGENE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA